What happened with BEAM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Beam Therapeutics is developing medicines for genetically defined diseases. Its technology chemically changes a targeted DNA base without cutting both strands of DNA, an approach called base editing. It develops both treatments that edit cells outside the body and treatments that deliver editors into the body, with internal capabilities for delivery and manufacturing.
Beam has no medicines approved for sale and has earned no product-sales revenue. Instead, pharmaceutical and biotechnology partners pay it under licensing and research collaboration agreements. These have included Apellis, Orbital and a now-completed Pfizer collaboration. Collaboration income depends on partners advancing programs and meeting payment milestones; royalties depend on eventual product sales. To sell its own medicines, Beam must complete clinical development and obtain regulatory approval. Until then, it relies on collaboration income and external financing to support development, while maintaining the third-party patent licenses its technology requires.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beam’s results hinge on clinical validation of its base-editing medicines and the economics of its collaborations, including the complement-disease partnership with Apellis, which is missing from this list.
CRISPR Therapeutics’ approved CASGEVY competes with Beam’s gene-edited sickle cell treatment still in development. CASGEVY’s safety, effectiveness and reimbursement for eligible patients with severe sickle cell disease set benchmarks for what Beam must offer.
Prime Medicine competes with Beam in alpha-1 antitrypsin deficiency, but also gives Beam rights to use its prime-editing technology for specified DNA changes, including edits to treat sickle cell disease. Its liver-disease clinical progress provides a comparison for Beam’s editing approach to alpha-1 antitrypsin deficiency.
Intellia Therapeutics’ advanced programs that edit genes inside the body provide clinical benchmarks for Beam’s liver-directed, nonviral base-editing medicines. Results from its Phase 3 lonvo-z and nex-z programs are the concrete comparison to watch.
Beam relies on patents licensed by Editas Medicine for parts of its base-editing platform, while Editas also develops competing medicines for sickle cell disease and beta thalassemia. Beam owes Editas milestone payments and royalties on covered product sales, so the patent coverage matters to Beam’s eventual product economics.
Wave Life Sciences develops RNA medicines that compete with Beam’s DNA-editing approach for patients with alpha-1 antitrypsin deficiency. Clinical evidence on effectiveness, safety and durability in that disease is the comparison to watch, rather than Wave’s broader collaboration revenue.
Vertex sells CASGEVY through authorized treatment centers, competing with Beam’s sickle cell gene-editing treatment still in development. CASGEVY’s uptake through those centers and access to third-party reimbursement show the commercial conditions Beam will face.
Beam depends on Pfizer to develop, manufacture and potentially sell the liver-directed base-editing candidate Pfizer licensed, with future milestones payable to Beam. Completion of the collaboration accounted for $109.1 million of Beam’s 2025 revenue; next, watch the candidate’s progress and Beam’s option to share development costs and profits after Phase 1/2.
Lilly acquired rights tied to cardiovascular programs using Beam’s base-editing technology and can owe Beam further development-stage payments. Watch specified clinical, regulatory and alliance events: Beam received no milestone payments under this agreement in 2025.
Fulcrum Therapeutics’ oral pociredir competes for sickle cell patients with Beam’s BEAM-101 gene-editing program. Pociredir’s clinical effectiveness is worth watching as a comparison between an oral medicine and Beam’s editing approach.
Arrowhead competes with Beam in alpha-1 antitrypsin deficiency by reducing gene activity rather than editing DNA. Its gene-silencing work for the disease’s liver manifestations provides a direct clinical comparison for Beam’s approach.
Beam’s alpha-1 antitrypsin deficiency editing treatment could, if approved, reduce demand for Kamada’s GLASSIA, which replaces AAT protein using a plasma-derived therapy. Kamada’s GLASSIA revenue is the exposed business line, though that risk depends on new treatments reaching approval.
Ultragenyx’s glycogen storage disease type Ia development effort competes with Beam’s BEAM-301 editing program for patients with R83C variants. Its clinical progress matters to Beam in a disease for which Ultragenyx says there are no pharmacologic treatments.
Fulcrum Therapeutics, Inc. earningsFULC
Fulcrum Therapeutics’ report will show how its oral pociredir is progressing in sickle cell disease, giving a patient-treatment comparison for Beam Therapeutics’ gene-editing program still in development.
Look for clinical evidence of pociredir’s effectiveness and whether its safety supports further development. Persuasive results would make an oral medicine a more credible alternative for the same sickle cell patients; limited evidence would leave that competitive case unproven, but would not establish how well Beam’s treatment works.
Eli Lilly & Co. earningsLLY
Lilly’s report may show development, regulatory or alliance progress in cardiovascular programs tied to Beam Therapeutics, which could determine whether Beam becomes eligible for further milestone payments.
Watch for a specific development, regulatory or alliance event that meets a payment condition. A qualifying event could bring Beam milestone revenue; without one, payment remains contingent on future progress rather than a recurring income stream.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex’s report will show whether CASGEVY is reaching patients through authorized treatment centers and securing reimbursement, a commercial-access test relevant to Beam Therapeutics’ future sickle cell treatment.
Look at CASGEVY’s use through treatment centers alongside reimbursement progress. Growing use with reimbursement in place would show that centers and payors can bring this type of treatment to patients; limited progress would signal access and payment hurdles Beam could also face if approved.
Beam Therapeutics Inc. earningsThis company
Beam Therapeutics has no product-sales revenue yet, so its report will show whether collaboration income is keeping pace with research costs and cash use.
Read collaboration revenue alongside research and development spending and cash used in operations. Rising partner revenue with contained cash use means collaboration payments are helping fund research; falling revenue or rising costs and cash use mean Beam must rely more on its existing resources or new financing to advance its programs.
Pfizer Inc. earningsPFE
Pfizer’s report may show progress on the liver-directed base-editing candidate it is developing under license from Beam Therapeutics, with implications for potential milestone payments and Beam’s later development-and-profit-sharing option.
Look for concrete candidate progress and whether it meets contractual payment conditions. Progress could bring Beam milestone revenue and allow it to assess its option to share later development costs and profits; a stalled program would leave both the potential payments and that option less valuable or less certain.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx’s report will show clinical progress in its glycogen storage disease type Ia program, a comparison for Beam Therapeutics’ BEAM-301 in patients with the R83C variant.
Check whether clinical progress includes patients with the R83C variant and whether the evidence supports effectiveness and safety. Strong progress would make Ultragenyx a more established competitor for that patient group; limited evidence would leave the comparison unresolved, not prove BEAM-301’s effectiveness.
Intellia Therapeutics, Inc earningsNTLA
Intellia Therapeutics’ report will show progress in its Phase 3 lonvo-z and nex-z programs, providing clinical benchmarks for Beam Therapeutics’ liver-directed in vivo base-editing medicines.
Look at the programs’ efficacy and safety data and whether they support continued development. Persuasive results would strengthen the clinical case for editing genes inside the body and offer a benchmark for Beam’s liver-directed programs; poor results would highlight risks, but the companies use different editing technologies, so outcomes are not interchangeable.
Prime Medicine, Inc. earningsPRME
Prime Medicine’s report will show clinical progress in its liver-disease program, a comparison for Beam Therapeutics’ editing approach to alpha-1 antitrypsin deficiency.
Look for evidence of patient benefit and whether safety supports further development. Strong evidence would make Prime a more credible competitor in this disease; limited evidence would leave the comparison incomplete, but would not establish how well Beam’s approach works.
Editas Medicine, Inc. earningsEDIT
Editas Medicine’s report may shed light on patent licenses Beam Therapeutics relies on and competing programs, both relevant to Beam’s development rights and eventual product economics.
Watch for developments or disputes involving the rights Beam licenses, and progress that could trigger payments. Clear rights and advancing programs support Beam’s ability to develop medicines, but eventual covered sales may carry milestone payments and royalties; restrictions or disputes could raise costs or constrain programs.
Wave Life Sciences Ltd. earningsWVE
Wave Life Sciences’ report will show clinical evidence for its RNA medicines in alpha-1 antitrypsin deficiency, a comparison for Beam Therapeutics’ DNA-editing approach.
Look at efficacy, safety and whether benefits persist in the disease program. Strong results would make RNA treatment a more credible alternative competing for the same patients; limited results would leave that comparison unproven, not show that Beam’s DNA-editing approach works.
